Spinal cord · 2026
Passive immunotherapy targeting pathogenic tau restores neuronal structure and function following spinal cord injury.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vahedi Amirreza, Rahimi Golnoosh, Rahbar Mohadeseh, Adibi Motlagh Yalda, Siahmansouri Pegah, Sorouri Farzaneh, Esmaily Farzaneh, Nabavi Seyed Massood, Kiani Sahar, Shahpasand Koorosh
Аннотация
STUDY DESIGN: Animal study.
OBJECTIVES: To determine whether eliminating cis pT231-tau with a specific monoclonal antibody can restore neuronal structure and function after spinal cord injury (SCI).
SETTING: Royan Institute, Tehran, Iran.
METHODS: Adult Wistar rats underwent SCI induction using the NYU impactor device. Animals received treatment with cis pT231-tau monoclonal antibody or placebo. Outcomes were assessed via immunostaining, immunoblotting, and the Basso, Beattie, and Bresnahan (BBB) behavioral test to evaluate motor function recovery.
RESULTS: Treatment with cis pT231-tau monoclonal antibody reduced inflammatory markers, enhanced myelin sheath formation, increased NF200 protein expression, and decreased GFAP levels compared with placebo. Behavioral testing indicated improved motor function in treated animals.
CONCLUSIONS: Eliminating cis pT231-tau using a specific monoclonal antibody mitigates neuronal damage and promotes structural and functional recovery following SCI, highlighting its therapeutic potential.
OBJECTIVES: To determine whether eliminating cis pT231-tau with a specific monoclonal antibody can restore neuronal structure and function after spinal cord injury (SCI).
SETTING: Royan Institute, Tehran, Iran.
METHODS: Adult Wistar rats underwent SCI induction using the NYU impactor device. Animals received treatment with cis pT231-tau monoclonal antibody or placebo. Outcomes were assessed via immunostaining, immunoblotting, and the Basso, Beattie, and Bresnahan (BBB) behavioral test to evaluate motor function recovery.
RESULTS: Treatment with cis pT231-tau monoclonal antibody reduced inflammatory markers, enhanced myelin sheath formation, increased NF200 protein expression, and decreased GFAP levels compared with placebo. Behavioral testing indicated improved motor function in treated animals.
CONCLUSIONS: Eliminating cis pT231-tau using a specific monoclonal antibody mitigates neuronal damage and promotes structural and functional recovery following SCI, highlighting its therapeutic potential.